Analysis of whether Zongatinib (Zongatinib) has been marketed in China and its sales information

Zongertinib (Zongertinib) is a new oral small molecule tyrosine kinase inhibitor (TKI) that mainly targets specific tumor targets and is used to treat patients with advanced tumors who are resistant to or relapsed with standard treatment options. As a precision targeted drug, zongatinib can effectively inhibit tumor-related signaling pathways, slow down tumor progression, improve patients' quality of life, and provide new treatment options for some patients with refractory tumors.

In the domestic market, Zovitinib has completed marketing approval. However, due to the short time to market, domestic pharmacies and hospitals may not have fully distributed the drug, making it difficult for patients to directly purchase the drug in the short term. The supply of drugs in domestic hospital pharmacies may be mainly concentrated in some large tertiary hospitals or designated institutions for clinical trials. Therefore, patients need to pay attention to hospital pharmacies and clinical guideline information to understand drug accessibility.

In overseas markets, the original drug Zongertinib has been launched. Taking the US market as an example, the price of each box of the drug is approximately 20 more than 10,000 yuan. This price reflects its research and development costs and clinical value as a new innovative drug. Currently, there is no generic version of zongatinib, so overseas original drugs are the only legally available source. For overseas patients or domestic patients imported through formal overseas channels, they need to plan their treatment budget in advance and choose reliable drug supply channels.

In terms of drug purchase and usage management, patients should obtain drugs through regular hospitals, certified pharmacies or legal import channels to ensure drug quality and safety. During use, it is necessary to strictly follow the doctor's prescription, take the medicine according to the course of treatment and dosage, and conduct regular follow-up visits to monitor tumor response, blood indicators and possible adverse reactions. Through standardized individualized treatment and scientific management, zongatinib can minimize safety risks while ensuring efficacy, and provide reliable treatment options for tumor patients.

Reference materials:https://www.drugs.com/